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In an era of shrinking international funding to address HIV, hepatitis C (HCV)  
and tuberculosis (TB), and competing priorities for domestic investment in health 
programmes, there is growing emphasis on ensuring value for money, efficient  
allocation of resources, and cost-effectiveness.
Compelling evidence from across the world shows that harm reduction 
interventions are cost-effective and can be cost-saving in the long-term. 
Advocates now need to make the investment case for harm reduction  
to donors, and increasingly to governments, as donors retreat. 
This advocacy work has never been more important. HIV continues to rise among  
people who inject drugs1, yet harm reduction funding is in crisis. Financial support  
for an effective HIV response for people who inject drugs in low- and middle-income 
countries totalled US$188 million in 2016 – just one-tenth of the US$1.5 billion that  
is needed annually by 2020.2 International donor funding for harm reduction has  
reduced by one-quarter over the past decade.3 Middle-income countries are increasingly 
vulnerable as donors either reduce or withdraw funding. While many governments are 
investing more in domestic health and HIV responses, few are substantially investing  
in harm reduction, even where the need is great.4 
Keeping the quality of services and communities at the centre
There is a legitimate worry among advocates that, if too much focus is put on cost-
effectiveness, governments and donors may prioritise finances over the quality of  
services being delivered, posing a threat to human rights-based, community-centred  
harm reduction.
In the face of this, the principle of ‘nothing about us without us’ must be staunchly upheld. 
Communities must be at the centre of all decisions that relate to their health, including 
financial ones. 
Economic analyses should not be the only basis on which budget decisions  
are made. Sustainable financing for health and harm reduction requires  
equity, human rights and community to be central. 
Considerable investment in programmes that aim to remove human rights barriers and 
reform punitive policies will be crucial if ending AIDS, TB, combating HCV, and achieving 
Universal Health Coverage by 2030 are to become more than a distant reality for people 
who use drugs.  
The cost-effectiveness of harm reduction:  
evidence from seven areas
The following brief provides the evidence advocates need to show the  
cost-effectiveness of harm reduction and the economic value that increased  
investment in such interventions will bring.
1    Needle and syringe programmes are one of the most cost-effective   
      public health interventions in existence 
UNAIDS estimates the average cost of a needle and syringe programme (NSP) to be US$23–71 per 
person per year.5 When the cost of treating the HIV and HCV infections that NSPs prevent is considered, 
NSPs are among the most cost-effective of all public health interventions.6,7   
An economic analysis of Australia’s 2000-2009 NSP found that, for every Australian dollar invested, more 
than four dollars were made in healthcare cost savings. By preventing new HIV infections, the NSP 
enabled the government to avoid significant costs associated with lifelong treatment. When a broader 
range of costs were taken into consideration, including productivity gains and losses, AU$27 were saved 
for every dollar invested.8 
A study in Odessa, Ukraine found that providing NSP, alongside condoms and HIV-related information, 
via two stationery and one mobile site prevented around 790 HIV infections in just one year, saving  
US$97 per HIV infection averted.9 Even with relatively low coverage levels of between 20-38%, the  
project was found to be both effective and cost-effective for HIV prevention. 
A study in Bangladesh indicates that early implementation of an NSP, when HIV prevalence among 
people who inject drugs is low, is more cost-effective than when prevalence is above 40%. However,  
both approaches were still found to be cost-effective.10 
Similarly, research from Yunnan province in China found NSPs to be cost-effective and cost-saving.  
The US$1.04 million spent on NSPs between 2002 and 2008 is estimated to have saved US$1.38-1.97 
million in HIV treatment and care costs due to the number of infections prevented.11 
2    Opioid substitution therapy is cost-effective for individuals and society 
Opioid substitution therapy (OST) is more expensive than NSP, costing between US$360-1,070 for 
methadone and US$1,230–3,170 for buprenorphine per person per year, but it is still cost-effective.12 
OST’s cost-effectiveness increases when wider societal benefits, such as reduced crime and incarceration, 
are factored into the analysis.13 
A study in Indonesia estimated that expanding OST coverage from 5% to 40% in West Java would avert 
approximately 2,400 HIV infections in eight years, at a cost of around US$7,000 per infection averted.14 
Similarly, in Russia evidence suggests OST would be highly cost-effective, as it would save considerable 
healthcare costs associated with HIV and TB.15  
Some studies compare the cost-effectiveness of different OST. For example, a trial in Vancouver, Canada 
found heroin-assisted treatment was more cost-effective than methadone maintenance therapy among 
people with chronic opioid dependence. When crime-related costs and out-of-pocket expenses were 
considered, heroin-assisted treatment also became cost-saving.16 
Combined harm reduction services are significantly more cost-effective  
than isolated services 
Substantial evidence indicates that combining NSP, OST and antiretroviral treatment (ART)  
is the most effective and cost-effective HIV strategy for people who inject drugs.17,18,19  
A study from Malaysia found the combined implementation of NSP and OST between 2006 and 2013  
was both effective and cost-effective in preventing HIV, and that its cost-effectiveness would increase  
over time. The cost-effectiveness of this integrated programming had the potential to be even greater, 
had coverage been higher and if wider individual and societal factors been considered.20  
In Slovakia, a study found that every Euro invested in harm reduction generated benefits worth three 
Euros, and every HCV infection averted would save €106,000 in treatment and quality-of-life costs over  
25 years.21  
Researchers in the United Kingdom found that a high coverage of combined NSP and OST reduces the 
risk of acquiring HCV by 29-71%. NSP was found to be cost-effective (and cost-saving in some settings)  
for HCV prevention. Conversely, removing OST and NSP would have a significantly detrimental impact  
on HCV epidemics. In one UK setting this would increase new HCV infections by 349% by 2031.22  
3
4    The peer distribution of naloxone is highly cost-effective  
Naloxone is a life-saving intervention that reverses opioid overdose. Peer distribution programmes 
provide naloxone to people who are likely to witness an overdose, such as friends and family of people 
who use opioids, alongside training on how to administer it. 
One study from the United States found naloxone peer distribution to be highly cost-effective in 
preventing overdose-related deaths.23 Similar results were found in a study in Russian cities.24  
5    Drug consumption rooms provide a high return on investment    
Drug consumption rooms vary in size, setting and approach, and therefore cost. Although they  
can be costly to establish, drug consumption rooms provide a high return on investment.   
In 2009, Canadian researchers concluded that Insite, Vancouver’s supervised injection facility,  
provided a societal benefit of US$6 million per year after implementation costs were accounted for.25 
Researchers in the United States examined the cost of introducing a supervised injecting facility  
in Baltimore, a city heavily affected by opioid overdoses. They found that an annual investment  
of US$1.8 million for one supervised injection room would result in US$7.8 million in savings.26 
6    Inaction, reducing funds or closing services have negative economic consequences
There is evidence that a decrease in, or total cessation of, harm reduction services can lead to a spike  
in HIV and/or HCV infections.
If Switzerland had discontinued harm reduction services in 2000, modelling showed there would have 
been a rapid re-emergence of the epidemic with 4,965 people acquiring HIV infection.27  
A study in Mexico found that the Global Fund for AIDS, Tuberculosis and Malaria’s withdrawal in  
2013 dramatically reduced access to harm reduction, with fewer outreach workers, and lower-quality  
harm reduction packs. This highlights the importance of responsible, paced transitions from donor 
funding to domestic support.28  
In Belarus, an eight-month funding gap reduced syringe distribution by 75%, which in turn reduced  
this intervention’s impact and cost-effectiveness. Without this gap, modelling suggests the programme 
would have averted 53% more HIV infections over eight months and 26% more over 22 months, and  
it would have cost 11% less to avert each infection.29  
7    The economic cost of punitive drug policies 
Many governments spend huge amounts on punitive drug policies. As well as violating human rights, 
this approach places a substantial economic burden on public health, society and the individual. Many 
countries imprison people for drug use and possession. This incarceration is expensive to fund and also 
incurs a huge public health cost. HIV prevalence, for example, is up to 50 times higher among prisoners 
than among the general public.30  
In several Asian countries, people who use drugs are sent to compulsory drug detention and 
rehabilitation centres, which UN agencies have condemned as ineffective and a violation of human  
rights. A study in Vietnam found detaining a person who injects drugs in a centre of this kind costs  
the local government 2.5 times more than providing them with OST in the community for a year.31 
Decriminalising personal drug use would save governments huge sums on law enforcement and 
incarceration, as exemplified by the Portuguese experience.32 Reallocating just 7.5% of drug control 
spending (US$7.66 billion) would result in a 94% reduction in new HIV infections among people who  
inject drugs, and a similar reduction in AIDS-related deaths by 2030.33, 34 This would effectively end  
HIV among people who inject drugs – something countries have committed to doing but are far  
from achieving. 
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